Drug reference
delta-9-tetrahydrocannabinol
Cannabinoid · Antiemetic
CannabinoidAntiemetic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Delta-9-tetrahydrocannabinol is a partial agonist at the CB1 cannabinoid receptor, targeting the endogenous cannabinoid system.
Indications
Antiemetic (particularly during chemotherapy)
Side effects
Common
Changes in moodChanges in perceptionChanges in motivationGiddinessIncreased hungerImpaired cognitive functionsImpaired perceptionImpaired reaction timeImpaired learningImpaired memoryImpaired coordinationImpaired tracking behaviorAnxiety (at higher doses)Reduced anxiety (at lower doses)
Serious
- Panic
- Hallucinations
- Acute psychosis
- Precipitation of psychosis in schizophrenia
- Transition to schizophrenia
Related guidelines
Other Cannabinoid drugs
Ask House about delta-9-tetrahydrocannabinol
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team